AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stages of its trials. The ...

psoriasis, and Crohn’s. A few days ago, ABBV was trading around $200, but its price has dropped by more than 12% in the last month, primarily due to emraclidine’s disappointing clinical trial results.